Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Immuneering CorpIMRX · Entity 5884 | CHIEF MEDICAL OFFICER | February 15, 2023 | February 17, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Immuneering Corp
Report date February 15, 2023 · Filed February 17, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.25 · Expires 2033-02-15 | Direct | 110,000 |
Reported balance
After 2023-02-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-15 · Grant · Acquired 110,000 · Balance 110,000 F1: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2023, and will be fully vested and exercisable on January 1, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2023, and will be fully vested and exercisable on January 1, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 15, 2023 Filed Feb 17, 2023 16:15 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 110,000 | $0.00 Strike: $4.25 | $0.00 |
DisclosureSEC source: 0001415889-23-002756 · form4-02172023_040208.xml · derivative · entry 1 Barrett Scott · CIK 0001869953 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Class A Common Stock · 110,000 shares Expires 2033-02-15 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2023, and will be fully vested and exercisable on January 1, 2027. Read SEC document |
| March 22, 2022 Filed Mar 22, 2022 18:49 UTC | Immuneering Corp IMRX · Entity 5884 | PurchaseClass A Common Stock | 900 | $7.49 | $6,736.50 |
DisclosureSEC source: 0001415889-22-003270 · form4-03222022_030337.xml · nonDerivative · entry 1 Barrett Scott · CIK 0001869953 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,563 F1 · price: This transaction was executed in multiple trades through a broker-dealer. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares acquired at each price. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 17:32 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 71,850 | $0.00 Strike: $9.66 | $0.00 |
DisclosureSEC source: 0001415889-22-001326 · form4-02142022_020230.xml · derivative · entry 1 Barrett Scott · CIK 0001869953 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,850 Underlying: Class A Common Stock · 71,850 shares Expires 2032-02-09 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2022, and will be fully vested and exercisable on January 1, 2026. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 06:04 UTC | Immuneering Corp IMRX · Entity 5884 | ConversionSeries B Preferred Stock · Derivative | 2,723 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-099725 · tm2123807-2_4seq1.xml · derivative · entry 4 Barrett Scott · CIK 0001869953 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 2,723 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 06:04 UTC | Immuneering Corp IMRX · Entity 5884 | ConversionSeries A Preferred Stock · Derivative | 3,273 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-099725 · tm2123807-2_4seq1.xml · derivative · entry 3 Barrett Scott · CIK 0001869953 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 3,273 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 06:04 UTC | Immuneering Corp IMRX · Entity 5884 | PurchaseClass A Common Stock | 667 | $15.00 | $10,005.00 |
DisclosureSEC source: 0001104659-21-099725 · tm2123807-2_4seq1.xml · nonDerivative · entry 2 Barrett Scott · CIK 0001869953 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,663 Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 06:04 UTC | Immuneering Corp IMRX · Entity 5884 | ConversionClass A Common Stock | 5,996 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-099725 · tm2123807-2_4seq1.xml · nonDerivative · entry 1 Barrett Scott · CIK 0001869953 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,996 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.